profit from every $100 of sales.
$0$100
Bone Biologics
We have no price for Bone Biologics since 12 October 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$7.70-0.00% today
-25.9% in 1 year
1-year low $3.501-year high $35.95
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Bone Biologics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bone Biologics | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads Bone Biologics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- 0.3×
- 0.0×
- –
- 1.0×
- -9.7%
- -206.7%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -60.2%
- -106.6%
- -59.5%
- -53.6%
- -60.2%
- –
Growth
- –
- –
- +34.8%
- –
- +128.6%
Financial health
- -1.7×
- 0.00
- 0.0%
- –
- 13.85
- 13.85
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 5%of 946
Bottom 21%of 872
Bottom 12%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.43 | -0.43 | +0.0% |
| Mar 2, 2026 | -0.58 | -0.34 | −70.6% |
| Nov 14, 2025 | -0.37 | -0.37 | −0.4% |
| Aug 14, 2025 | -1.33 | -0.58 | −128.9% |
| May 12, 2025 | -0.32 | -3.24 | +90.1% |
| Dec 31, 2023 | -2.90 | – | – |
| Jun 30, 2023 | -1.69 | – | – |
| Mar 31, 2023 | -0.27 | – | – |
News
Regeneron wins FDA nod for rare bone disorder therapySeeking Alpha · Aug 19, 2026The newest story we have is from Aug 19, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
79Pass
Philip Fisher
40No pass
Peter Lynch
60Pass
Joel Greenblatt
50No pass
Charlie Munger
35No pass
Terry Smith
32No pass
Questions about Bone Biologics
Is Bone Biologics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bone Biologics AI analysis
What does Bone Biologics do?
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. It is in Medical - Devices.
Does Bone Biologics pay a dividend?
No. Bone Biologics does not pay a dividend at the moment.
How has Bone Biologics stock done over the past year?
Down 25.9% over the past twelve months, to $7.70. It traded between $3.50 and $35.95 and is 78.6% below its high.
Who are Bone Biologics's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Bone Biologics's.
Prices: daily closes to Oct 12, 2026. Fundamentals: company reports via invest-like data.